Get the Daily Brief
Latest Biotech News
PacBio posts better‑than‑expected Q4 — consumables hit record
Pacific Biosciences reported Q4 revenue of $44.6 million, up 14% year‑over‑year, driven by a record for consumables and growth across clinical market adoption. The company shipped Revio and Vega...
Thermo Fisher inks Datavant deal — secure RWD linkage for trials
Thermo Fisher Scientific’s PPD clinical research unit formed a strategic partnership with Datavant to enable privacy‑preserving linkage of de‑identified research datasets with real‑world patient...
Madrigal buys Ribo siRNAs — $60M now, $4.4B possible
Madrigal Pharmaceuticals signed a global licensing agreement with Ribo Life Science and Ribocure to acquire six preclinical siRNA programs targeting metabolic dysfunction‑associated...
Microbiotica MB‑310 induces remission in phase Ib — promising UC signal
Microbiotica reported positive Phase Ib data for MB‑310, an oral live biotherapeutic for ulcerative colitis, with 12 of 19 treated patients achieving clinical remission versus 3 of 10 on placebo....
FDA refuses-to-file Moderna flu shot: review halted
The FDA issued a refusal-to-file letter for Moderna’s mRNA influenza vaccine application, halting regulatory review. The letter was signed by Vinay Prasad, director of the agency’s office...
BridgeBio’s oral dwarfism drug wins Phase III — filing planned
BridgeBio reported positive top-line results from Propel 3: oral infigratinib improved annualized height velocity in children with achondroplasia versus placebo. The trial met its primary endpoint...
Ultragenyx cuts 10% as FDA requests more manufacturing documents
Ultragenyx disclosed a 10% workforce reduction—about 130 roles—while refocusing resources after two failed late‑stage trials in osteogenesis imperfecta and continuing FDA scrutiny of its gene...
CareDx’s AlloHeme shows high sensitivity — commercial launch eyed
CareDx announced validation data from the ACROBAT observational study for AlloHeme, its allogeneic hematopoietic cell transplant surveillance assay. The assay delivered 85% sensitivity and 92%...
Microbiotica’s live microbiome pill posts positive Phase Ib remission data
Microbiotica reported positive Phase Ib results for MB‑310, an oral live biotherapeutic for ulcerative colitis. In the randomized study, 12 of 19 treated patients achieved clinical remission...
Madrigal buys six Ribo siRNA programs — deal could top $4.4B
Madrigal Pharmaceuticals struck a licensing deal with Suzhou Ribo Life Science and Ribocure to acquire six preclinical siRNA programs targeting metabolic dysfunction‑associated steatohepatitis...
Viking advances oral GLP‑1/GIP into phase III obesity trial
Viking Therapeutics announced plans to advance its oral dual GLP‑1/GIP receptor agonist VK‑2735 into a Phase III obesity program, targeting a Q3 2026 start. VK‑2735 is being developed in both...
Quantx closes $85M Series B to start clinical trials for oral immunology drugs
Quantx Biosciences closed an oversubscribed $85 million Series B to advance two oral small‑molecule immunology candidates into the clinic: a STAT6 inhibitor and an IL‑17 inhibitor. The financing...
ILiAD raises $115M to push intranasal pertussis vaccine toward Phase III
ILiAD Biotechnologies secured $115 million in a Series B financing led by RA Capital to advance BPZE1, a live attenuated intranasal pertussis vaccine, into pivotal testing. The company plans a...
Thermo Fisher and Datavant partner to link clinical RWD at scale
Thermo Fisher Scientific’s PPD clinical research business partnered with Datavant to enable privacy‑preserving tokenization and linkage of real‑world data across more than 350 partners and 80,000...
FDA refuses to review Moderna flu vaccine: rare refuse-to-file
The FDA issued a refuse-to-file (RTF) decision for Moderna’s mRNA influenza vaccine mRNA-1010, marking an uncommon regulatory rebuke for a high-profile vaccine developer. Moderna said the agency...
BridgeBio’s oral drug wins phase III – infigratinib speeds growth in dwarfism
BridgeBio disclosed positive top-line results from Propel 3, a global Phase 3 trial testing oral infigratinib in children with achondroplasia. Infigratinib demonstrated a statistically significant...
Madrigal inks $60M deal with Ribo – adds siRNA MASH portfolio
Madrigal Pharmaceuticals agreed a global licensing partnership with Suzhou Ribo Life Science and Ribocure Pharmaceuticals to acquire six preclinical siRNA programs targeting metabolic...
ILiAD raises $115M to push pertussis vaccine into phase III
ILiAD Biotechnologies closed a $115 million Series B led by RA Capital to advance its live attenuated intranasal pertussis vaccine BPZE1 toward Phase III testing. ILiAD plans a pivotal human...
CareDx’s AlloHeme shows high sensitivity and long lead time in transplant surveillance
CareDx reported validation data from the ACROBAT observational study supporting AlloHeme, its cell‑free DNA assay for allogeneic hematopoietic cell transplant surveillance. AlloHeme achieved 85%...
Seres cuts 30% of staff, pauses lead program in strategic reset
Microbiome specialist Seres announced a strategic reboot that will cut roughly 30% of its workforce and pause its lead program while refocusing resources on earlier‑stage, immunology‑focused...